Xenon Pharmaceuticals Inc. (XENE)
| Market Cap | 3.60B |
| Revenue (ttm) | 7.50M |
| Net Income (ttm) | -345.91M |
| Shares Out | 83.19M |
| EPS (ttm) | -4.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,686,182 |
| Open | 45.40 |
| Previous Close | 44.92 |
| Day's Range | 42.01 - 46.99 |
| 52-Week Range | 26.74 - 46.99 |
| Beta | 0.93 |
| Analysts | Strong Buy |
| Price Target | 53.70 (+24.22%) |
| Earnings Date | Feb 26, 2026 |
About XENE
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The com... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for XENE stock is "Strong Buy." The 12-month stock price target is $53.7, which is an increase of 24.22% from the latest price.
News
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
Phase 3 X-TOLE2 topline data for azetukalner in FOS expected first half of March 2026 Five additional Phase 3 studies of azetukalner continue to enroll in epilepsy and neuropsychiatry indications with...
Polarean Expands Xenon MRI Platform into Cardiopulmonary Drug Development with Multi-Center PH-ILD Study
Innovative Trial Design to Directly Measure Microvascular Functional Effects of Inhaled Therapy at the Capillary level of Pulmonary Hypertension Patients with Interstitial Lung Disease (PH-ILD) Innova...
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, British Columbia and BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clini...
Xenon Pharmaceuticals Inc. (XENE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Xenon Pharmaceuticals Inc. (XENE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference
VANCOUVER, British Columbia and BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clini...
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference
VANCOUVER, British Columbia and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clini...
Xenon Pharmaceuticals: Derisked Pipeline Ahead Of Critical 2026 Phase 3 Readout
Xenon Pharmaceuticals (XENE) is undervalued given azetukalner's late-stage potential to transform epilepsy and mood disorder treatment. XENE's $555M cash position supports operations into 2027, reduci...
Xenon Pharmaceuticals Inc. (XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation Transcript
Xenon Pharmaceuticals Inc. (XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation Transcript
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025
VANCOUVER, British Columbia and BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clini...
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025
VANCOUVER, British Columbia and BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clini...
Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025
Seven posters to be presented, including new X-TOLE OLE data supporting the ability to attain and regain extended periods of seizure freedom with long-term use of azetukalner Data will also highlight ...
Xenon to Present at Upcoming Investor Conferences
VANCOUVER, British Columbia and BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clini...
Xenon Pharmaceuticals Inc. (XENE) Q3 2025 Earnings Call Transcript
Xenon Pharmaceuticals Inc. ( XENE) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Colleen Alabiso Ian Mortimer - President, CEO, Principal Accounting Officer & Director Chris...
Xenon Reports Third Quarter 2025 Financial Results & Business Update
– Phase 3 X-TOLE2 FOS topline data on track to read out early 2026 with patient randomization complete – Phase 3 X-NOVA2 and X-NOVA3 studies in MDD & Phase 3 X-CEED study in BPD continuing to recruit...
Xenon to Report Q3 2025 Financial Results on November 3, 2025
VANCOUVER, British Columbia and BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clini...
Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer
Mr. Kelly is a proven strategic CFO with significant financial, operational and commercialization leadership experience Mr. Kelly is a proven strategic CFO with significant financial, operational and ...
Xenon Pharmaceuticals Inc. - Special Call
Xenon Pharmaceuticals Inc. - Special Call Company Participants Ian Mortimer - Interim CFO, President, CEO, Principal Financial Officer, Principal Accounting Officer & Director James Empfield - Executi...
Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain
VANCOUVER, British Columbia and BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clin...
Xenon Pharmaceuticals: Pushing Azetukalner Towards Finish Line With Phase 3 2026 Data Release
Xenon Pharmaceuticals is advancing azetukalner in multiple phase 3 trials for focal onset seizures, with topline X-TOLE2 data expected in early 2026. Azetukalner's mechanism and prior dose-dependent e...
Xenon Pharmaceuticals Inc. (XENE) Q2 2025 Earnings Call Transcript
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q2 2025 Earnings Conference Call August 11, 2025 4:30 PM ET Company Participants Chad Fugere - Vice President, Investor Relations Christopher John Kenney - Ch...
Xenon Reports Second Quarter 2025 Financial Results & Business Update
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026 – Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED...
Xenon to Report Q2 2025 Financial Results on August 11, 2025
VANCOUVER, British Columbia and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developi...
Xenon Joins the Russell 3000® and Russell 2000® Indexes
VANCOUVER, British Columbia and BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developi...
Xenon Announces Appointment of Darren Cline as Chief Commercial Officer
Mr. Cline brings extensive commercial expertise to lead the transition of Xenon to a commercial-stage company with the anticipated launch of azetukalner across three potential indications Mr. Cline br...
Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
VANCOUVER, British Columbia and BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developi...